Recursion Pharmaceuticals (NasdaqGS:RXRX) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBen Taylor - CFO and President of Recursion UKDave Hallett - Chief Scientific OfficerNajat Khan - CEO and PresidentNajat KhanGood morning, everyone, thank you so much for joining us. I want to start by briefly framing where Recursion is today in its journey and evolution. Over the past decade, Recursion has built something truly special, a differentiated platform, pioneering the integration of l ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsBen Taylor - CFO and President of Recursion UKDave Hallett - Chief Scientific OfficerNajat Khan - CEO and PresidentNajat KhanGood morning, everyone, thank you so much for joining us. I want to start by briefly framing where Recursion is today in its journey and evolution. Over the past decade, Recursion has built something truly special, a differentiated platform, pioneering the integration of l ...

Core Insights - Lunai Bioworks has identified three clinically relevant subtypes of Parkinson's disease and prioritized drug targets, which may enhance proof-of-concept programs and facilitate strategic partnerships in a growing $13 billion market [1][6]. Company Overview - Lunai Bioworks is an AI-powered biotechnology company focused on developing precision therapeutics [1][7]. - The company utilizes its proprietary Augusta Platform to integrate large-scale proteomic data with clinical phenotyping to uncover subtypes of Parkinson's disease [2][6]. Research Findings - The analysis involved longitudinal clinical and proteomic data from over 650 participants, utilizing 4,500 proteomic probes over a median of 2.5 years, with some participants tracked for up to 5 years [3]. - Three patient subtypes linked to outcomes were identified, which can improve trial success rates and asset valuation [4][6]. - Progression-linked targets and biomarker candidates were identified to support patient stratification and treatment response assessment [5][6]. Market Potential - The current market for Parkinson's disease therapies is estimated at $6-8 billion, projected to exceed $13 billion by the 2030s due to rising prevalence and unmet medical needs [6][7]. Strategic Initiatives - The company is pursuing co-development and partnership opportunities with biopharmaceutical companies to enhance therapeutic development [6][8]. - By integrating molecular biology with clinical phenotyping, the company aims to identify precision targets that could transform Parkinson's therapy development [6][8].

Core Insights - Nurix Therapeutics presented new clinical data for bexobrutideg, a BTK degrader, showing an objective response rate (ORR) of 75.0% in heavily pre-treated Waldenström macroglobulinemia patients [1][4] - The drug demonstrated durable responses and was well tolerated, with no dose-limiting toxicities reported [2][3] - The company aims to position bexobrutideg as a best-in-class therapeutic option for various hematological malignancies [2] Clinical Data Summary - The Phase 1 trial included 31 patients with a median age of 71 years and a median of 3 prior lines of therapy [2][4] - Among the patients, 77.4% had MYD88 mutations and 19.4% had CXCR4 mutations, with 100% having prior BTK inhibitor treatment [2] - The ORR included very good partial responses (VGPR) in 10.7% of patients, partial responses (PR) in 50.0%, and minor responses (MR) in 14.3% [4] Safety and Tolerability - Bexobrutideg was well tolerated, with common adverse events being low grade, including neutropenia (29.0%) and diarrhea (25.8%) [3] - No new onset atrial fibrillation was observed, and only two treatment-emergent adverse events led to drug discontinuation [3] Future Development - The company plans to expand the development of bexobrutideg into chronic lymphocytic leukemia (CLL) and other non-Hodgkin lymphoma (NHL) indications [2][8] - Nurix is also advancing multiple other drug candidates in its pipeline, focusing on targeted protein degradation [9]

Core Insights - Rakovina Therapeutics is set to present new data at the Society for Neuro-Oncology Annual Meeting, focusing on AI-driven cancer therapies targeting DNA-damage response inhibitors for brain cancers [1][2]. Presentation Details - The company will showcase two posters on November 21, 2025, detailing the discovery and development of CNS-penetrating ATR and PARP1-selective inhibitors [3][4]. - The first poster discusses the kt-5000AI ATR inhibitor program, developed with Variational AI, highlighting the discovery of potent ATR inhibitors effective against treatment-resistant tumors [3]. - The second poster covers the kt-2000AI PARP inhibitor program, utilizing the Deep Docking™ platform for virtual screening of billions of compounds to identify CNS-penetrant inhibitors [4]. Company Overview - Rakovina Therapeutics focuses on innovative cancer treatments, leveraging AI technologies like Deep-Docking™ and Enki™ to enhance drug candidate optimization [7][8]. - The company aims to advance its pipeline of DNA-damage response inhibitors into human clinical trials in collaboration with pharmaceutical partners [8].

Core Insights - Lunai Bioworks has announced a significant advancement in its second-generation allogeneic dendritic cell therapy, demonstrating complete regression of both primary and metastatic pancreatic tumors in humanized mouse models [1][3][5]. Group 1: Scientific Breakthrough - The study published in the journal "Vaccines" details the development of a clinical-grade dendritic cell construct that achieved complete tumor regression in preclinical models [3][4]. - The therapy utilizes engineered dendritic cells derived from stem cells, which are genetically enhanced to activate the immune system against cancer [3][5]. - The second-generation construct features improved design and manufacturing attributes while maintaining therapeutic efficacy, crucial for future clinical applications [4][5]. Group 2: Clinical Implications - The next-generation dendritic cell therapy has shown robust activation of cytotoxic T cells and NK cells, leading to significant anti-tumor activity [5][6]. - Lunai's therapy not only targets pancreatic cancer but also has potential applications across a wide range of solid tumors [5]. Group 3: Company Positioning - The CEO of Lunai Bioworks emphasized that this development marks a critical transition from research to clinical translation, positioning the company at the forefront of next-generation cell-based immunotherapies [6]. - Lunai Bioworks is focused on leveraging AI in drug discovery and biodefense, aiming to redefine therapeutic innovation while addressing emerging threats [7].

Core Insights - Rakovina Therapeutics presented new data on its AI-driven kt-5000AI drug discovery program for ATR inhibitors at the AACR-NCI-EORTC conference, highlighting promising results for cancer therapy targeting CNS penetration [1][2][3] Company Developments - The collaboration with Variational AI utilized the Enki™ generative AI platform to identify novel small-molecule candidates for CNS-penetrant ATR inhibition, with multiple lead compounds achieving the desired profile [2][3] - Rakovina's kt-5000AI program is advancing next-generation ATR inhibitors that have confirmed CNS exposure, potentially benefiting patients with primary brain tumors and brain metastases [3][5] - The company aims to advance one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners [6] Scientific Findings - In cell-based assays, lead compounds demonstrated over 50% inhibition of ATR activity below 200 nM, with potency exceeding reference compounds such as ceralasertib, tuvusertib, and elimusertib [7] - In vivo pharmacokinetic studies showed measurable drug concentrations in plasma and brain tissue after intraperitoneal dosing at 5 mg/kg, indicating CNS penetration and good tolerability after single-dose administration [7]

Core Insights - Shuttle Pharmaceuticals is transitioning from a focus on radiation therapy to a broader mission of enhancing scientific intelligence through artificial intelligence [2][3] - The company has signed a Letter of Intent to acquire Molecule.ai for approximately $10 million, which will allow it to leverage AI for scientific reasoning and discovery [3][4] Company Update - The acquisition of Molecule.ai will enable Shuttle to train AI models that can predict molecular interactions and recognize patterns, thus transforming the drug discovery process [6][9] - This shift positions Shuttle as a leader in creating a feedback network where insights build upon each other, enhancing the overall discovery process [7][11] Industry Implications - The integration of AI in drug discovery is not just about speed but about comprehension, allowing for a deeper understanding of molecular behavior and potential side effects [8][9] - The ability to learn from past experiments will create a multiplier effect in drug discovery, enabling a scalable platform that can lead to multiple discoveries from a single insight [10][12] Future Outlook - The future of biotechnology may evolve beyond traditional definitions, with companies like Shuttle becoming hybrid entities that combine laboratory work with advanced algorithms [12][14] - The focus will shift from the number of patents filed to the improvement of AI models, indicating a new paradigm in measuring success in the biotech industry [12][14]

Core Insights - Adagene Inc. announced that its lead product ADG126 will be featured in two oral presentations at the CSCO Meeting in Jinan, China, from September 10-14, 2025 [1] Group 1: Clinical Developments - ADG126, a masked anti-CTLA-4 SAFEbody, is currently in Phase 1b/2 clinical studies in combination with pembrolizumab for treating advanced microsatellite-stable colorectal cancer (MSS CRC) [6][7] - The combination therapy has shown an objective response rate (ORR) of approximately 30% and over 80% disease control in refractory/resistant MSS CRC patients without liver metastasis, with a median overall survival (OS) of 19.4 months in the 10 mg/kg cohort [3] Group 2: Presentations at CSCO Meeting - Dr. Xu Ruihua will present updated results of the ADG126-P001 study on September 11, 2025, focusing on the efficacy of ADG126 combined with pembrolizumab in advanced MSS CRC [2] - Dr. Heinz-Josef Lenz will discuss the role of anti-CTLA-4 therapy in metastatic CRC, emphasizing the potential of ADG126 in treating cold tumors like MSS CRC [3] Group 3: Company Overview - Adagene Inc. is a clinical-stage biotechnology company focused on developing novel antibody-based cancer immunotherapies using its proprietary SAFEbody technology [4][5] - The company employs computational biology and artificial intelligence to design antibodies that meet unmet patient needs, and it has established strategic collaborations to enhance its research capabilities [4]

Core Insights - Renovaro Inc. has received a Notice of Allowance for a new patent that enhances its AI and machine learning capabilities in drug discovery [1][2] - The patent focuses on integrating diverse biomedical data sources into a standardized framework for predictive modeling, addressing a critical need in the biopharma industry [2][4] - This development is seen as a strategic milestone for Renovaro, reinforcing its position in the growing market for data-driven therapeutics [3][4] Company Overview - Renovaro aims to accelerate precision and personalized medicine through AI and biotechnology platforms, focusing on early diagnosis and targeted treatments [5] - The company includes subsidiaries such as RenovaroBio, which specializes in cell-gene immunotherapy, and RenovaroCube, which leverages AI for multi-omic diagnostics [5] Patent Details - The new patent introduces methods for real-time, reproducible predictive analytics across distributed computing environments, essential for improving efficiency in biopharma [4][7] - This patent builds on a previously granted patent that protects machine learning pipeline optimization, enhancing Renovaro's foundational intellectual property [7] Market Implications - The patent addresses the integration of siloed and heterogeneous data, a significant challenge in pharmaceutical R&D and clinical practice [7] - It enhances Renovaro's commercial potential by enabling scalable biomedical analytics across various applications, including rare diseases and personalized medicine [7]